2004_CD
SkyePharma_NN
Annual_JJ
Report_NN
21_CD
International_NN
Financial_NN
Reporting_GER
Standards_NN
The_DT
2004_CD
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
UK_NN
IAS_NN
19_CD
:_:
Employee_NN
benefits_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
,_,
SkyePharmas_NN
historic_JJ
In_PIN
accordance_NN
with_PIN
IFRS1_NN
,_,
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
elect_VB
to_TO [SPIN]
fully_AMP
recognize_VB [PRIV]
all_QUAN
primary_JJ
reporting_GER
GAAP_NN
._.
From_PIN
1_CD
January_NN
2005_CD
SkyePharma_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_PIN
actuarial_JJ
gains_NN
and_PHC
losses_NN
on_PIN
its_PIT
pension_NN
scheme_NN
in_PIN
France_NN
at_PIN
1_CD
January_NN
prepare_VB
its_PIT
consolidated_JJ
financial_JJ
statements_NOMZ
under_IN
International_NN
Financial_NN
2004_CD
,_,
its_PIT
transition_NOMZ
date_NN
to_PIN
IFRS_NN
._.
Subject_JJ
to_PIN
the_DT
endorsement_NOMZ
by_PIN
the_DT
Reporting_GER
Standards_NN
IFRS_NN
._.
These_DEMO
standards_NN
represent_VPRT
a_DT
significant_JJ
change_NN
European_NN
Union_NN
of_PIN
IAS_NN
19_CD
revised_VBN
,_,
ongoing_JJ
actuarial_JJ
gains_NN
and_PHC
losses_NN
will_PRMD
from_PIN
UK_NN
GAAP_NN
._.
While_OSUB
SkyePharmas_NN
first_RB
published_VBD
IFRS_NN
financial_JJ
statements_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
Statement_NOMZ
of_PIN
Recognised_NN
Income_NN
and_PHC
Expenditure_NN
._.
will_PRMD
be_VB [BEMA]
its_PIT
interim_JJ
results_NN
for_PIN
June_NN
2005_CD
,_,
guidance_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
as_IN
to_PIN
the_DT
key_JJ
differences_NN
that_TOBJ
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
arise_VB
on_PIN
the_DT
adoption_NOMZ
of_PIN
IFRS_NN
._.
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
:_:
Financial_NN
Instruments_NOMZ
The_NN
Group_NN
intends_VPRT [SUAV]
to_TO
communicate_VB
further_JJ
details_NN
of_PIN
the_DT
impact_NN
of_PIN
adopting_VBG
One_CD
of_PIN
the_DT
exemptions_NOMZ
available_JJ
under_IN
IFRS1_NN
relaxes_VPRT
the_DT
requirement_NOMZ
IFRS_NN
on_PIN
the_DT
2004_CD
results_NN
during_PIN
the_DT
first_JJ
half_NN
of_PIN
2005_CD
._.
to_TO
present_VB
comparative_JJ
information_NOMZ
on_PIN
financial_JJ
instruments_NOMZ
for_PIN
2004_CD
in_PIN
the_DT
2005_CD
financial_JJ
statements_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
anticipate_VB [PRIV]
utilising_VBG
Assumptions_NOMZ
this_DEMO
exemption_NOMZ
,_,
and_ANDC
expects_VPRT [PRIV]
to_TO [SPIN]
retrospectively_RB
apply_VB
IAS_NN
32_CD
Financial_NN
The_DT
financial_JJ
impact_NN
of_PIN
the_DT
transition_NOMZ
to_PIN
IFRS_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
based_VBN
upon_PIN
Instruments_NOMZ
:_:
Disclosure_NN
and_PHC
presentation_NOMZ
and_PHC
IAS_NN
39_CD
Financial_NN
the_DT
assumption_NOMZ
that_TOBJ
all_QUAN
IFRS_NN
standards_NN
issued_VBN [WZPAST]
by_PIN
the_DT
International_NN
Accounting_GER
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
which_WDT [WHOBJ]
for_PIN
many_QUAN
financial_JJ
Standards_NN
Board_NN
IASB_NN
that_TSUB
are_VPRT [BEMA]
effective_PRED
for_PIN
2005_CD
reporting_GER
are_VPRT [PASS]
endorsed_VBN
instruments_NOMZ
will_PRMD
be_VB [BEMA]
fair_JJ
value_NN
._.
At_PIN
present_JJ
,_,
the_DT
European_JJ
Commission_NN
has_VPRT [PEAS]
not_XX0
endorsed_VBN
all_QUAN
of_PIN
these_DEMO
standards_NN
._.
Although_CONC
the_DT
IASB_NN
has_VPRT [PEAS]
issued_VBN
all_QUAN
standards_NN
IAS_NN
21_CD
:_:
The_DT
Effects_NN
of_PIN
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
that_TSUB
will_PRMD
be_VB [BEMA]
compulsory_PRED
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
,_,
some_QUAN
new_JJ
An_DT
exemption_NOMZ
offered_VBN [WZPAST]
by_PIN
IFRS_NN
1_CD
in_PIN
respect_NN
of_PIN
IAS_NN
21_CD
The_DT
Effects_NN
of_PIN
standards_NN
may_POMD
be_VB [BEMA]
available_PRED
for_PIN
early_TIME
adoption_NOMZ
,_,
changes_NN
are_VPRT [SPAU] [PASS]
still_RB
anticipated_VBN [PRIV]
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
gives_VPRT
the_DT
Group_NN
the_DT
option_NOMZ
to_TO
reset_VB
to_PIN
others_NN
and_CC
the_DT
interpretation_NOMZ
and_PHC
application_NOMZ
of_PIN
certain_JJ
recently_TIME
revised_VBN
its_PIT
cumulative_JJ
translation_NOMZ
differences_NN
to_PIN
zero_CD
at_PIN
1_CD
January_NN
2004_CD
,_,
its_PIT
date_NN
standards_NN
is_VPRT [SPAU]
still_RB
being_VBG [PASS]
debated_VBN
._.
Therefore_CONJ
the_DT
current_JJ
position_NOMZ
with_PIN
respect_NN
of_PIN
transition_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
to_TO
take_VB
this_DEMO
exemption_NOMZ
,_,
and_ANDC
will_PRMD
to_PIN
IFRS_NN
may_POMD
be_VB [BEMA]
subject_PRED
to_TO
change_VB
._.
continue_VB
to_TO
include_VB
its_PIT
cumulative_JJ
translation_NOMZ
differences_NN
within_PIN
equity_NOMZ
._.
This_DEMP
is_VPRT
because_CAUS
the_DT
information_NOMZ
is_VPRT [BEMA]
readily_RB
available_PRED
and_CC
will_PRMD
be_VB [BEMA]
consistent_JJ
Transition_NOMZ
Date_NN
and_PHC
Comparative_NN
Information_NOMZ
with_PIN
its_PIT
reporting_GER
under_IN
US_FPP1
GAAP_NN
._.
The_DT
IASB_NN
issued_VBD
IFRS_NN
1_CD
First_JJ
time_NN
adoption_NOMZ
of_PIN
international_JJ
financial_JJ
reporting_GER
standards_NN
in_PIN
June_NN
2003_CD
._.
This_DEMP
deals_VPRT
with_PIN
how_RB
companies_NN
will_PRMD
have_VB
to_TO
apply_VB
Key_NN
differences_NN
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
._.
IFRS_NN
1_CD
requires_VPRT [SUAV]
that_THVC
comparative_JJ
information_NOMZ
be_VB [BEMA]
The_DT
key_JJ
differences_NN
that_TOBJ
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
arise_VB
on_PIN
the_DT
adoption_NOMZ
restated_VBN [WZPAST]
for_PIN
all_QUAN
years_NN
that_TOBJ
a_DT
full_JJ
set_NN
of_PIN
comparatives_NN
is_VPRT [PASS]
provided_VBN
._.
Therefore_CONJ
,_,
of_PIN
IFRS_NN
are_VPRT
:_:
the_DT
Groups_NN
IFRS_VPRT
transition_NOMZ
date_NN
is_VPRT [BEMA]
1_CD
January_NN
2004_CD
._.
revenue_NN
recognition_NOMZ
differences_NN
in_PIN
respect_NN
of_PIN
up_RB
front_JJ
payments_NOMZ
:_:
IFRS_NN
1_CD
Exemptions_NOMZ
accounting_VBG [WZPRES]
for_PIN
the_DT
sale_NN
of_PIN
royalty_NN
interests_NN
to_PIN
Paul_NN
Capital_NN
:_:
In_PIN
general_JJ
a_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
determine_VB [SUAV] [PRIV]
its_PIT
IFRS_NN
accounting_GER
policies_NN
and_CC
the_DT
inclusion_NN
of_PIN
a_DT
fair_JJ
value_NN
charge_NN
in_PIN
respect_NN
of_PIN
outstanding_JJ
employee_NN
apply_VB
these_DEMO
retrospectively_RB
to_TO
determine_VB [SUAV] [PRIV] [THATD]
its_PIT
opening_VBG
balance_NN
sheet_NN
,_,
in_PIN
our_FPP1
case_NN
share_NN
options_NOMZ
:_:
at_PIN
1_CD
January_NN
2004_CD
,_,
under_IN
IFRS_NN
at_PIN
its_PIT
transition_NOMZ
date_NN
._.
However_CONJ
IFRS_NN
1_CD
permits_VPRT
the_DT
cessation_NOMZ
of_PIN
amortisation_NOMZ
of_PIN
goodwill_NN
:_:
those_DEMO
companies_NN
adopting_VBG [WZPRES]
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
to_TO
take_VB
some_QUAN
exemptions_NOMZ
accounting_VBG [WZPRES]
for_PIN
convertible_JJ
bonds_NN
:_:
and_ANDC
from_PIN
the_DT
full_JJ
requirements_NOMZ
of_PIN
IFRS_NN
in_PIN
the_DT
transition_NOMZ
period_NN
._.
the_DT
capitalization_NOMZ
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
._.
The_DT
key_JJ
IFRS_NN
1_CD
transitional_JJ
provisions_NN
the_DT
Group_NN
proposes_VPRT [SUAV]
to_TO
adopt_VB
are_VPRT
Revenue_NN
Recognition_NOMZ
outlined_VBN
below_PLACE
._.
Under_IN
IFRS_NN
SkyePharma_NN
will_PRMD
adopt_VB
a_DT
revenue_NN
recognition_NOMZ
policy_NN
in_PIN
accordance_NN
with_PIN
IAS_NN
18_CD
which_WDT
is_VPRT [BEMA]
similar_PRED
to_PIN
that_DEMP
applied_VBN
under_IN
US_FPP1
GAAP_NN
._.
Under_IN
UK_NN
GAAP_NN
IFRS_VPRT
3_CD
:_:
Business_NOMZ
combinations_NOMZ
Skye_NN
has_VPRT [SPAU] [PEAS]
generally_RB
recognized_VBN [PRIV]
up_RP
front_JJ
payments_NOMZ
immediately_TIME
in_PIN
full_JJ
where_RB
A_DT
first_JJ
time_NN
adopter_NN
has_VPRT
the_DT
option_NOMZ
not_XX0
to_TO
restate_VB
most_EMPH
aspects_NN
of_PIN
past_JJ
there_EX
are_VPRT
no_SYNE
material_NN
future_NN
obligations_NOMZ
and_CC
the_DT
milestones_NN
are_VPRT
nonbusiness_NOMZ
combinations_NOMZ
and_ANDC
instead_CONJ
to_TO
apply_VB
IFRS_NN
3_CD
prospectively_RB
from_PIN
the_DT
refundable_JJ
,_,
on_PIN
the_DT
basis_NN
that_TOBJ
the_DT
up_RP
front_NN
is_VPRT [BEMA]
a_DT
payment_NOMZ
for_PIN
past_JJ
services_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
SkyePharma_NN
will_PRMD
elect_VB
this_DEMO
option_NOMZ
._.
In_PIN
this_DEMO
Under_IN
IFRS_NN
generally_RB
up_RB
front_JJ
payments_NOMZ
will_PRMD
be_VB [PASS]
deferred_VBN
and_PHC
amortised_VBN
case_NN
goodwill_NN
would_PRMD
remain_VB
largely_RB
as_IN
under_IN
UK_NN
GAAP_NN
and_PHC
amortisation_NOMZ
on_PIN
a_DT
systematic_JJ
basis_NN
over_IN
the_DT
period_NN
of_PIN
development_NOMZ
to_PIN
filing_NN
._.
This_DEMP
is_VPRT [BEMA]
similar_PRED
would_PRMD
stop_VB
at_PIN
1_CD
January_NN
2004_CD
,_,
SkyePharmas_NN
proposed_VBD [SUAV]
transition_NOMZ
date_NN
._.
to_PIN
the_DT
treatment_NOMZ
adopted_VBN
under_IN
US_FPP1
GAAP_NN
._.
However_CONJ
,_,
the_DT
accounting_GER
for_PIN
each_QUAN
agreement_NOMZ
will_PRMD
need_VB
to_TO
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
an_DT
individual_JJ
basis_NN
._.
IFRS_NN
2_CD
:_:
Share_NN
based_VBN
payments_NOMZ
IFRS_VPRT
2_CD
applies_VPRT
to_PIN
unvested_JJ
equity_NOMZ
instruments_NOMZ
,_,
such_JJ
as_IN
share_NN
options_NOMZ
,_,
Sale_NN
of_PIN
Royalty_NN
Interests_NN
granted_VBD [SUAV]
since_OSUB
7_CD
November_NN
2002_CD
and_CC
not_XX0
vested_VBN
at_PIN
1_CD
January_NN
2005_CD
._.
However_CONJ
Under_IN
IFRS_NN
SkyePharma_NN
will_PRMD
account_VB
for_PIN
the_DT
sale_NN
of_PIN
royalty_NN
interests_NN
to_PIN
Paul_NN
under_IN
the_DT
transitional_JJ
arrangements_NOMZ
of_PIN
IFRS_NN
1_CD
,_,
there_EX
is_VPRT
the_DT
option_NOMZ
to_TO
adopt_VB
Capital_NN
on_PIN
a_DT
similar_JJ
basis_NN
to_PIN
that_DEMO
under_IN
US_FPP1
GAAP_NN
._.
Under_IN
IFRS_NN
the_DT
proceeds_NN
full_JJ
retrospective_NN
application_NOMZ
of_PIN
the_DT
standard_NN
where_RB
companies_NN
have_VPRT [PEAS]
received_VBN
from_PIN
Paul_NN
Capital_NN
meet_VPRT
the_DT
definition_NOMZ
of_PIN
a_DT
financial_JJ
liability_NOMZ
under_IN
IAS_NN
previously_TIME
publicly_RB
disclosed_VBN [PUBV]
the_DT
fair_JJ
value_NN
of_PIN
those_DEMO
equity_NOMZ
instruments_NOMZ
32_CD
,_,
and_ANDC
will_PRMD
be_VB [PASS]
treated_VBN
as_IN
debt_NN
._.
No_SYNE
other_JJ
operating_GER
income_NN
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
measurement_NOMZ
date_NN
._.
SkyePharma_NN
has_VPRT [SPAU] [PEAS]
previously_TIME
disclosed_VBN [PUBV]
under_IN
IFRS_NN
,_,
royalties_NN
paid_VBD
to_PIN
Paul_NN
Capital_NN
will_PRMD
be_VB [PASS]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
the_DT
those_DEMO
fair_JJ
values_NN
in_PIN
its_PIT
US_FPP1
GAAP_NN
disclosures_NN
and_CC
expects_VPRT [PRIV]
to_TO
adopt_VB
full_JJ
debt_NN
and_PHC
interest_NN
will_PRMD
be_VB [PASS]
charged_VBN
on_PIN
the_DT
debt_NN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
proceeds_NN
retrospective_JJ
application_NOMZ
._.
received_VBN [PASTP]
from_PIN
Paul_NN
Capital_NN
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
sale_NN
and_CC
recorded_VBN
as_IN
other_JJ
operating_GER
income_NN
and_PHC
royalties_NN
are_VPRT [PASS]
expensed_VBN
when_RB
incurred_VBN
._.
22_CD
SkyePharma_NN
Annual_JJ
Report_NN
2004_CD
International_NN
Financial_NN
Reporting_GER
Standards_NN
continued_VBD
Share_NN
Based_VBN
Payments_NOMZ
IFRS_VPRT
2_CD
requires_VPRT [SUAV]
that_THVC
for_PIN
share_NN
option_NOMZ
awards_NN
to_PIN
employees_NN
,_,
the_DT
fair_JJ
value_NN
of_PIN
the_DT
employee_NN
services_NN
received_VBD
should_NEMD
be_VB [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
share_NN
option_NOMZ
at_PIN
the_DT
grant_NN
date_NN
._.
This_DEMP
is_VPRT [BEMA]
significantly_RB
different_PRED
from_PIN
the_DT
current_JJ
treatment_NOMZ
in_PIN
the_DT
UK_NN
where_RB
the_DT
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
the_DT
exercise_NN
price_NN
._.
Since_OSUB
SkyePharma_NN
has_VPRT [SPAU] [PEAS]
historically_RB
granted_VBN [SUAV]
employee_NN
options_NOMZ
where_RB
the_DT
share_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
equals_VPRT
the_DT
exercise_NN
price_NN
,_,
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
charge_NN
to_PIN
record_NN
._.
The_DT
charge_NN
under_IN
IFRS_NN
will_PRMD
be_VB [BEMA]
the_DT
same_JJ
as_IN
that_DEMO
previously_TIME
disclosed_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
standard_JJ
FAS_NN
123_CD
._.
Goodwill_NN
Amortisation_NOMZ
UK_NN
GAAP_NN
requires_VPRT [SUAV]
goodwill_NN
to_TO
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
expected_VBN [PRIV]
useful_JJ
life_NN
which_WDT [WHOBJ]
the_DT
Directors_NN
have_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
is_VPRT [BEMA]
20_CD
years_NN
._.
Under_IN
IFRS_NN
,_,
goodwill_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_CC
so_RB
is_VPRT [PASS]
not_XX0
amortised_VBN
,_,
but_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
testing_GER
._.
Therefore_CONJ
the_DT
annual_JJ
goodwill_NN
charge_NN
made_VBN
under_IN
UK_NN
GAAP_NN
will_PRMD
not_XX0
be_VB [PASS]
recorded_VBN
under_IN
IFRS_NN
from_PIN
1_CD
January_NN
2004_CD
,_,
the_DT
IFRS_NN
transition_NOMZ
date_NN
._.
Convertible_JJ
Bond_NN
Under_IN
UK_NN
GAAP_NN
the_DT
net_JJ
proceeds_NN
of_PIN
the_DT
convertible_JJ
bond_NN
issue_NN
were_VBD [PASS]
recorded_VBN
as_IN
debt_NN
._.
Under_IN
IFRS_NN
the_DT
convertible_JJ
bonds_NN
will_PRMD
be_VB [PASS]
bifurcated_VBN
and_CC
the_DT
conversion_NN
option_NOMZ
deducted_VBN [WZPAST]
from_PIN
the_DT
debt_NN
and_CC
classified_VBN
as_IN
equity_NOMZ
._.
This_DEMP
will_PRMD
lead_VB
to_PIN
higher_JJ
interest_NN
charges_NN
under_IN
IFRS_NN
than_PIN
under_IN
UK_NN
GAAP_NN
._.
Furthermore_CONJ
the_DT
Group_NN
is_VPRT [BEMA]
likely_PRED
to_TO
record_VB
a_DT
one_CD
off_PIN
gain_NN
or_CC
loss_NN
on_PIN
the_DT
exchange_NN
of_PIN
the_DT
2005_CD
bonds_NN
for_PIN
the_DT
2024_CD
bonds_NN
._.
No_SYNE
such_JJ
gain_NN
or_CC
loss_NN
arises_VPRT
under_IN
UK_NN
GAAP_NN
._.
Research_NN
and_PHC
Development_NOMZ
Under_IN
IFRS_NN
the_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
capitalize_VB
research_NN
and_PHC
development_NOMZ
when_RB
the_DT
criteria_NN
as_IN
laid_VBN
out_PIN
in_PIN
IAS_NN
38_CD
are_VPRT [PASS]
met_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
reviewed_VBN
its_PIT
current_JJ
projects_NN
and_CC
determined_VBD [SUAV] [PRIV]
that_THVC
the_DT
capitalization_NOMZ
of_PIN
certain_JJ
expenditure_NN
may_POMD
be_VB [BEMA]
appropriate_PRED
._.
Future_JJ
projects_NN
may_POMD
lead_VB
to_PIN
the_DT
capitalization_NOMZ
of_PIN
further_JJ
expenditure_NN
._.
